Pricing, reimbursement, market access, and business intelligence professional.

Especial interest and expertise in rare disease, haemato-oncology, and cell & gene therapy, presenting regularly at health economics and market access conferences.

MPharm from the University of Lisbon, with postgraduate diploma in Pharmacoeconomics from Lisbon School of Economics & Management.

We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. Our company was founded by an entrepreneur who embarked on a life-long journey to transform the lives of those living with devastating conditions when two of his children were diagnosed with a rare disease. That spirit of empathy, compassion, and tenacity permeates our culture and influences all aspects of our approach to advancing cutting-edge technologies.